Kalaris Therapeutics (KLRS) EBT (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly EBT of -$16.5 million for Q1 2026, up 69.98% year-over-year from -$9.7 million in Q1 2025, and down 52.94% quarter-over-quarter from -$10.8 million in Q4 2025.
Kalaris Therapeutics (KLRS) EBT (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' EBT history runs 8 years deep, the most recent figure standing at -$16.5 million for Q1 2026.
- In Q1 2026, EBT rose 69.98% year-over-year to -$16.5 million; the TTM figure through Mar 2026 stood at -$60.3 million (up 43.53% YoY), while the FY2025 annual figure was -$55.7 million, up 5.23% from the prior year.
- EBT for Q1 2026 stood at -$16.5 million, down from -$10.8 million in the prior quarter.
- The five-year high for EBT was -$2.7 million in Q1 2024, with the low at -$245.4 million in Q4 2023.
- The 5-year median for EBT is -$38.7 million (2024), against an average of -$42.3 million.
- The sharpest annual moves came in 2024 and 2025: EBT soared 96.56% in 2024, then plunged 1908.69% in 2025.
- Kalaris Therapeutics' EBT stood at -$38.6 million in 2022, then sank by 536.64% to -$245.4 million in 2023, then jumped by 96.56% to -$8.4 million in 2024, then slipped by 27.94% to -$10.8 million in 2025, then plunged by 52.94% to -$16.5 million in 2026.
- Business Quant data shows KLRS's EBT at -$16.5 million in Q1 2026, -$10.8 million in Q4 2025, and -$18.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Kalaris Therapeutics | 95.90 Mn | 95.90 Mn | - | -12.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.08 Mn |
| Mar 31, 2026 | -16.52 Mn |
| Dec 31, 2025 | -10.80 Mn |
| Sep 30, 2025 | -18.61 Mn |
| Jun 30, 2025 | -14.38 Mn |
| Mar 31, 2025 | -55.02 Mn |
| Dec 31, 2024 | -8.44 Mn |
| Sep 30, 2024 | -38.66 Mn |
| Jun 30, 2024 | -4.69 Mn |
| Mar 31, 2024 | -2.74 Mn |
| Dec 31, 2023 | -245.43 Mn |
| Sep 30, 2023 | -44.27 Mn |
| Jun 30, 2023 | -45.27 Mn |
| Mar 31, 2023 | -45.16 Mn |
| Dec 31, 2022 | -38.55 Mn |
| Sep 30, 2022 | -42.07 Mn |
| Jun 30, 2022 | -44.49 Mn |
| Mar 31, 2022 | -43.86 Mn |
| Dec 31, 2021 | 163.07 Mn |
| Sep 30, 2021 | -45.51 Mn |